HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
TRAPPC9
trafficking protein particle complex subunit 9
Chromosome 8 Β· 8q24.3
NCBI Gene: 83696Ensembl: ENSG00000167632.19HGNC: HGNC:30832UniProt: Q96Q05
85PubMed Papers
21Diseases
0Drugs
82Pathogenic Variants
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
cerebral cortex developmentprotein bindingTRAPP complextrans-Golgi networkintellectual disability, autosomal recessive 13intellectual disability-obesity-brain malformations-facial dysmorphism syndromegenetic disorderautosomal recessive non-syndromic intellectual disability
✦AI Summary

TRAPPC9 (trafficking protein particle complex subunit 9) is a multifunctional protein with roles in both cellular trafficking and immune signaling. As a component of the TRAPP-II complex, TRAPPC9 mediates vesicle tethering and transport from the endoplasmic reticulum to the Golgi apparatus, as well as intra-Golgi and endosome-to-Golgi trafficking in mammalian cells 1. Beyond vesicular transport, TRAPPC9 functions as a modulator of NF-ΞΊB signaling by regulating IKK complex phosphorylation and activation 1. The protein exhibits preferential maternal allele expression (~70%) and plays critical roles in neurogenesis and neuronal differentiation 2. Biallelic loss-of-function mutations in TRAPPC9 cause autosomal recessive intellectual disability syndrome (NIBP Syndrome/MRT13), characterized by profound developmental delay, microcephaly, speech disorders, and brain atrophy 34. Recent findings extend the disease phenotype to include autism spectrum disorder, obesity, dysmorphic features, and abnormal N-glycosylation consistent with congenital disorder of glycosylation (TRAPPC9-CDG) 56. Maternal allele loss produces more severe pathology than paternal loss, reflecting the gene's imprinting 2. TRAPPC9 dysfunction impairs vesicle trafficking and lipid metabolism, contributing to neurological manifestations 7. These findings establish TRAPPC9 as essential for brain development and metabolic homeostasis.

Sources cited
1
TRAPPC9 is a subunit of TRAPP-II complex important for ER-to-Golgi and intra-Golgi transport, and modulates NF-ΞΊB activation
PMID: 30272317
2
TRAPPC9 exhibits ~70% maternal allele expression bias and heterozygous maternal loss causes phenotypes similar to homozygous loss; involved in brain development and energy balance
PMID: 32877400
3
TRAPPC9 mutations cause autosomal recessive intellectual disability with speech disorder and microcephaly
PMID: 29031008
4
TRAPPC9/NIBP regulates NF-ΞΊB signaling and protein trafficking; mutations cause NIBP Syndrome with intellectual disability, obesity, and microcephaly
PMID: 32434006
5
TRAPPC9 deficiency causes intellectual disability with dysmorphic features and abnormal N-glycosylation (TRAPPC9-CDG)
PMID: 35042660
6
TRAPPC9 mutations associated with intellectual disability, autism, cortical atrophy, and acquired microcephaly
PMID: 38467738
7
TRAPPC9 loss-of-function disrupts vesicle trafficking and affects lipid droplet accumulation, causing developmental delay and microcephaly
PMID: 34983975
Disease Associationsβ“˜21
intellectual disability, autosomal recessive 13Open Targets
0.77Strong
intellectual disability-obesity-brain malformations-facial dysmorphism syndromeOpen Targets
0.53Moderate
genetic disorderOpen Targets
0.52Moderate
autosomal recessive non-syndromic intellectual disabilityOpen Targets
0.50Moderate
Abnormality of the nervous systemOpen Targets
0.45Moderate
autism spectrum disorderOpen Targets
0.41Moderate
Intellectual disabilityOpen Targets
0.41Moderate
Intellectual disability - obesity - brain malformations - facial dysmorphismOpen Targets
0.37Weak
cervical carcinomaOpen Targets
0.37Weak
pyelonephritisOpen Targets
0.32Weak
ovarian neoplasmOpen Targets
0.31Weak
Abnormal nasolacrimal system morphologyOpen Targets
0.28Weak
biliary tract diseaseOpen Targets
0.28Weak
nephrotic syndromeOpen Targets
0.28Weak
viral pneumoniaOpen Targets
0.27Weak
adverse effectOpen Targets
0.26Weak
circadian rhythm sleep disorderOpen Targets
0.25Weak
respiratory system diseaseOpen Targets
0.25Weak
essential hypertensionOpen Targets
0.25Weak
stomatitisOpen Targets
0.25Weak
Intellectual developmental disorder, autosomal recessive 13UniProt
Pathogenic Variants82
NM_001160372.4(TRAPPC9):c.1414C>T (p.Arg472Ter)Pathogenic
Intellectual disability, autosomal recessive 13|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2026β†’ Residue 472
NM_001160372.4(TRAPPC9):c.531dup (p.Leu178fs)Pathogenic
Intellectual disability, autosomal recessive 13|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 178
NM_001160372.4(TRAPPC9):c.289G>T (p.Glu97Ter)Pathogenic
not provided|Inborn genetic diseases|Intellectual disability, autosomal recessive 13
β˜…β˜…β˜†β˜†2024β†’ Residue 97
NM_031466.8(TRAPPC9):c.-124dupPathogenic
Intellectual disability, autosomal recessive 13|not provided
β˜…β˜…β˜†β˜†2024
NM_001160372.4(TRAPPC9):c.367G>T (p.Glu123Ter)Pathogenic
Intellectual disability, autosomal recessive 13|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2024β†’ Residue 123
NM_001160372.4(TRAPPC9):c.1840C>T (p.Arg614Ter)Pathogenic
Intellectual disability, autosomal recessive 13|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 614
NM_001160372.4(TRAPPC9):c.2491C>T (p.Arg831Ter)Pathogenic
Abnormality of the nervous system|not provided|Intellectual disability, autosomal recessive 13
β˜…β˜…β˜†β˜†2024β†’ Residue 831
NM_001160372.4(TRAPPC9):c.2854G>T (p.Glu952Ter)Pathogenic
not provided|Intellectual disability, autosomal recessive 13
β˜…β˜…β˜†β˜†2024β†’ Residue 952
NM_001160372.4(TRAPPC9):c.2841dup (p.Glu948Ter)Pathogenic
not provided|Intellectual disability, autosomal recessive 13
β˜…β˜…β˜†β˜†2024β†’ Residue 948
NM_031466.8(TRAPPC9):c.-204C>TPathogenic
not provided
β˜…β˜…β˜†β˜†2023
NM_001160372.4(TRAPPC9):c.274_280del (p.Trp92fs)Pathogenic
not provided|TRAPPC9-related disorder
β˜…β˜…β˜†β˜†2022β†’ Residue 92
NM_001160372.4(TRAPPC9):c.1129C>T (p.Arg377Ter)Pathogenic
Intellectual disability, autosomal recessive 13|Abnormality of the nervous system|not provided
β˜…β˜…β˜†β˜†2022β†’ Residue 377
NM_001160372.4(TRAPPC9):c.151C>T (p.Arg51Ter)Pathogenic
Intellectual disability|Intellectual disability, autosomal recessive 13|Malignant tumor of esophagus
β˜…β˜…β˜†β˜†2020β†’ Residue 51
NM_001160372.4(TRAPPC9):c.2700-2A>TLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2026
NM_001160372.4(TRAPPC9):c.1818T>G (p.Tyr606Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 606
NM_031466.8(TRAPPC9):c.-124delPathogenic
not provided
β˜…β˜†β˜†β˜†2025
NM_001160372.4(TRAPPC9):c.2964+2T>CLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2025
NM_001160372.4(TRAPPC9):c.865C>T (p.Gln289Ter)Pathogenic
Intellectual disability, autosomal recessive 13
β˜…β˜†β˜†β˜†2025β†’ Residue 289
NM_031466.8(TRAPPC9):c.-196G>APathogenic
not provided
β˜…β˜†β˜†β˜†2025
NM_001160372.4(TRAPPC9):c.1929C>G (p.Tyr643Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 643
View on ClinVar β†—
Related Genes
TRAPPC14Protein interaction100%RAB1AProtein interaction100%TRAPPC8Protein interaction100%TRAPPC12Protein interaction100%TRAPPC11Protein interaction100%TRAPPC6AProtein interaction100%
Tissue Expression6 tissues
Brain
100%
Heart
62%
Bone Marrow
58%
Ovary
47%
Liver
46%
Lung
46%
Gene Interaction Network
Click a node to explore
TRAPPC9TRAPPC14RAB1ATRAPPC8TRAPPC12TRAPPC11TRAPPC6A
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q96Q05
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.79LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.65 [0.54–0.79]
RankingsWhere TRAPPC9 stands among ~20K protein-coding genes
  • #5,647of 20,598
    Most Researched85
  • #909of 5,498
    Most Pathogenic Variants82 Β· top quartile
  • #6,458of 17,882
    Most Constrained (LOEUF)0.79
Genes detectedTRAPPC9
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
TRAPPC9: Novel insights into its trafficking and signaling pathways in health and disease (Review).
PMID: 30272317
Int J Mol Med Β· 2018
1.00
2
Expanding the genetic and phenotypic spectrum of TRAPPC9 and MID2-related neurodevelopmental disabilities: report of two novel mutations, 3D-modelling, and molecular docking studies.
PMID: 38467738
J Hum Genet Β· 2024
0.90
3
Emerging role of NIK/IKK2-binding protein (NIBP)/trafficking protein particle complex 9 (TRAPPC9) in nervous system diseases.
PMID: 32434006
Transl Res Β· 2020
0.80
4
Identification of a novel homozygous TRAPPC9 gene mutation causing non-syndromic intellectual disability, speech disorder, and secondary microcephaly.
PMID: 29031008
Am J Med Genet B Neuropsychiatr Genet Β· 2017
0.70
5
TRAPPC9-CDG: A novel congenital disorder of glycosylation with dysmorphic features and intellectual disability.
PMID: 35042660
Genet Med Β· 2022
0.60